Current Weather
The Spy FM

First Malaria Vaccine Moves A Step Closer To Approval

Filed by KOSU News in Health.
October 8, 2013

A malaria vaccine studied in more than 15,000 African children has been found to reduce the number of cases of disease by 27 to 46 percent.

That’s only modest efficacy compared to most accepted vaccines. But this would be the first anti-malarial immunization on the market, and its developers emphasize that it still prevents a lot of cases. Its main sponsor, GlaxoSmithKline, says it’s good enough to justify seeking regulatory approval in 2014.

Specifically, for every 1,000 toddlers who had the three-dose vaccination, there were 941 fewer cases of malaria over the following 18 months. Those who didn’t get the vaccine had 1,800 cases per 1,000 children — a rate reflecting the fact that most of them suffer more than one case a year.

Preventing 941 cases for every 1,000 young children vaccinated “suggests that it has potential for a pretty big public health impact,” says Dr. David Kaslow of the PATH Malaria Vaccine Initiative, one of the study’s sponsors. “Those are some pretty big numbers of cases averted.”

The new data, presented Tuesday at a malaria vaccine conference in Durban, South Africa, extends results released last November, which gave the first indication that this vaccine, called RTS,S, has limited effectiveness.

But Dr. Moncef Slaoui, chief of vaccine development at GlaxoSmithKline, says even a vaccine of modest effectiveness can have a big impact because malaria is such a monumental problem in Africa.

“Malaria in sub-Saharan Africa kills around 600,000 children every year, which is an enormous number,” Slaoui tells Shots. He’s been working on the RTS,S vaccine for nearly 30 years.

The African study, which involves 11 sites in seven countries, couldn’t demonstrate the vaccine’s impact on malaria deaths. That’s because children in the study all got the very best treatment, so very few died of the disease. But those who got the vaccine were 36 percent less likely than those who didn’t to get severe malaria, which often results in death for many victims.

Still, malaria specialists acknowledge that it’s not going to be easy to decide how to use the RTS,S vaccine.

The new data show that 18 months after vaccination, it’s 46 percent effective in preventing illness in children immunized between 5 months and 17 months of age. For infants younger than that, it was only 27 percent effective. Those efficacy rates are somewhat lower than shorter-term results presented last year, indicating that the protection falls off a bit over time.

Work is underway to see if a booster shot can strengthen that protection.

“There’s no question that everybody would want a higher efficacy on this vaccine,” says Dr. Johanna Daily of Einstein Medical College. Standard vaccines against other diseases have over 80 percent, sometimes 90 percent, efficacy, she says. “But malaria has always been such a challenge. And we may not ever get those levels.”

Even when people actually catch malaria — the most effective, though undesirable, form of immunization — protection against future infection is far from complete.

“It’s hard to improve upon nature,” Daily says. “So perhaps … a more efficacious vaccine is unlikely, and therefore [RTS,S] would be the thing to go with.”

About two dozen other malaria vaccines are in the pipeline. Some target more than one protein on the malaria parasite’s surface, and some aim to protect at more than one stage in the parasite’s complex life cycle. But it’s going to be awhile before anyone knows if these other candidate vaccines are more effective than RTS,S.

Meanwhile, if the World Health Organization gives the green light to the Glaxo vaccine, it’s going to have to compete for scarce public health funds with other malaria-prevention measures, such as insecticide-treated bed nets to keep malaria-infected mosquitoes away from sleeping children.

Figuring out the vaccine’s role in malaria prevention is “going to be a very tough question,” Daily says.

“Each country is going to have a pot of money and [is] going to have to decide how to spend it,” she says. “Should it go to vaccine? Should it go to bed nets? Should it go to diagnosis? Should it go to community health workers? Each Minister of Health can decide if this is something they want to put their money toward.”

Glaxo has pledged to keep the cost of the vaccine low — no more than the cost of production plus a 5 percent profit that the company says it will devote to developing other vaccines against neglected diseases. Slaoui says RTS,S won’t be pennies per dose. Most likely, it’ll be a few dollars. [Copyright 2013 NPR]

Leave a Reply

11AM to 12PM The Story

The Story

The Story with Dick Gordon brings the news home through first-person accounts. The live weekday program is passionate, personal, immediate and relevant to listeners, focusing on the news where it changes our lives, causes us to stop and rethink, inspires us.

Listen Live Now!

12PM to 1PM Fresh Air

Fresh Air

This one-hour program features Terry Gross' in-depth interviews with prominent cultural and entertainment figures, as well as distinguished experts on current affairs and news.

View the program guide!

1PM to 2PM Talk of the Nation

Talk of the Nation

Journalist Neal Conan leads a productive exchange of ideas and opinions on the issues that dominate the news landscape.

View the program guide!

Upcoming Events in your area (Submit your event today!)

Streaming audio and podcasts

Stream KOSU on your smartphone

Phone Streaming

SmartPhone listening options on this page are intended for many iPhones, Blackberries, etc. with low-cost software applications available to listen to our full-time web streams, both News on KOSU-1 and Classical on KOSU-2.

Learn more about our complete range of streaming services

We're perfecting the patient experience - Stillwater Medical Center